Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Multiple safety-related claims are unsupported or overgeneralized relative to the provided label excerpts, including claims about long-term effects, seizure recurrence after discontinuation, persistence of neuropsychiatric effects, and comparative incidence statements. The label excerpt provided does support certain items (e.g., withdrawal gradual over at least 1 week to minimize increased seizure frequency, neuropsychiatric adverse events can occur, and need for caution/monitoring related to dizziness/ataxia and cardiac conduction).
Category Scores
Accurate Statements
Withdrawal from lacosamide has been reported to cause symptoms such as headache, nausea, and dizziness.
Not supported in the provided label excerpts.
Withdrawal from lacosamide has been reported to cause symptoms such as headache, nausea, and dizziness.
Not supported; see unsupported/omissions.
Unsupported Statements
There is a risk of adverse effects associated with lacosamide, including those that may occur in the long term.
The provided excerpts do not state that long-term adverse effects specifically occur or quantify/describe long-term risk.
Some lacosamide adverse effects may persist even after discontinuation of the medication.
The provided excerpts do not state that adverse effects generally or specific neuropsychiatric effects persist after discontinuation.
Long-term use of lacosamide is linked to an increased risk of seizure recurrence.
The provided excerpts discuss withdrawal should be gradual to minimize increased seizure frequency, but do not link long-term use to increased seizure recurrence risk.
Patients who experienced seizure recurrence on lacosamide therapy were more likely to experience a prolonged period of seizures.
No such comparative/associative clinical study finding is present in the provided excerpts.
Lacosamide is associated with neuropsychiatric effects including cognitive impairment, depression, anxiety, and psychosis.
The provided excerpts list 'Suicidal Behavior and Ideation' as a serious adverse reaction, but do not list cognitive impairment, depression, anxiety, or psychosis or explicitly connect them to lacosamide.
Patients taking lacosamide experienced a higher incidence of neuropsychiatric adverse events compared to those receiving placebo.
The provided excerpts do not include incidence comparisons for neuropsychiatric adverse events versus placebo.
Neuropsychiatric effects associated with lacosamide can persist even after discontinuation.
No persistence-after-discontinuation statement for neuropsychiatric effects appears in the provided excerpts.
Withdrawal from lacosamide has been reported to cause symptoms such as headache, nausea, and dizziness.
The provided excerpts only state withdrawal should be gradual to minimize increased seizure frequency; they do not list withdrawal symptom types such as headache, nausea, and dizziness.
Patients who discontinued lacosamide therapy experienced a higher incidence of withdrawal symptoms compared to those who remained on the medication.
No comparative incidence of withdrawal symptoms is provided in the excerpts.
The US FDA recommends healthcare providers closely monitor patients taking lacosamide for signs of adverse effects, including seizure recurrence, neuropsychiatric effects, and withdrawal symptoms.
The provided excerpts include specific warnings (e.g., withdrawal gradually, suicidal behavior/ideation, dizziness/ataxia, cardiac conduction abnormalities) but do not contain an FDA 'recommendation' statement about 'closely monitor' for seizure recurrence, neuropsychiatric effects, and withdrawal symptoms as a grouped monitoring directive.
Contradictions
Important Omissions
Indication should specify patient age range for partial-onset seizures (treatment of partial-onset seizures in patients 1 month of age and older) rather than only stating 'partial-onset seizures.'
Importance:
Moderate
If discussing stopping lacosamide, the label excerpt specifies withdrawal should be gradual over a minimum of 1 week to minimize increased seizure frequency; the user's statements focus on withdrawal symptoms rather than including this required taper duration detail.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about persistence of adverse effects and seizure recurrence risk after long-term use are unsupported by the provided label excerpts and may mislead interpretation of risk; however, the label excerpt does support that withdrawal should be gradual and notes key safety risks (suicidal behavior/ideation; dizziness/ataxia; cardiac conduction abnormalities).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple safety claims are not supported by the provided VIMPAT label excerpts (especially neuropsychiatric effect specifics, persistence after discontinuation, seizure recurrence linked to long-term use, and withdrawal symptom examples/incidence comparisons).
Suggested Improvement
Restrict statements to label-supported items from the provided excerpts: partial-onset indication wording with age, gradual withdrawal over minimum 1 week to minimize increased seizure frequency, suicidal behavior/ideation risk, dizziness/ataxia, and cardiac rhythm/conduction caution; remove unsupported persistence and placebo-incidence/comparative assertions not present in the excerpts.